WALTHAM, Mass., May 25, 2022--ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
ImmunoGen (IMGN) gets priority review from the FDA for the BLA seeking approval for its lead candidate, mirvetuximab soravtansine, for treating platinum-resistant ovarian cancer.
WALTHAM, Mass., May 23, 2022--ImmunoGen Announces Acceptance of Biologics License Application for Mirvetuximab Soravtansine in Ovarian Cancer by US FDA with Priority Review